Male contraceptive pill appears to be safe without side effects in early trials
The new hormone-free pill, which aims to decrease sperm count reversibly, was found to be safe in a trial of 16 male volunteers.
For decades, the choice of contraception for men has been limited to condoms and vasectomy.
Weight gain, acne, mood changes and changes in libido were some of the side effects of previous attempts to create a male contraceptive pill.
However, women have several contraceptive options, including the pill, implant and intrauterine device (IUD) - many of which also come with unappealing side effects.
But because this new male pill does not use hormones, it gives hope for fewer negative side effects in comparison to prior attempts, the early-stage research published in Communications Medicine reveals.
The researchers, scientists at drug development company YourChoice Therapeutics, said: 'Since nearly half of all pregnancies in the US and worldwide are unintended, there is a critical need for additional contraceptive options for men and women.'
The new drug uses a chemical known as YCT-529, which works by blocking vitamin A metabolites from binding to receptors in the testes, preventing sperm from being produced.
Professor Alan Pacey, an andrologist at the University of Manchester, who was not part of the study, told BBC Radio 4's Today programme: "This molecule targets a compound which is related to vitamin A, retinoic acid, and we have known for a long time that this compound is important in how sperm are produced in the testis, making it the perfect target for a male contraceptive pill.
'It is able to inhibit that process without altering the sex hormones, which give men a sex drive.'
Previous animal studies have found that using the chemical can create reversible infertility without side effects.
In the recent trial, 16 male volunteers aged between 32 and 59 took the drug twice in increasing doses – 10mg, 30mg, 90mg and 180mg – while some took the placebo for comparison.
Participants were monitored for 15 days to assess side-effect and hormone levels.
The study authors concluded: 'Administration of single oral doses of 10–180 mg YCT-529, fasted, and 30 mg, fed, is well tolerated by healthy male subjects.
'YCT-529 does not demonstrate an adverse cardiac safety profile, or change in haematology, coagulation or serum chemistry parameters, hormone or proinflammatory cytokine levels, sexual drive and mood, and shows good bioavailability (with no clear food effect).'
Speaking on the Today programme, Dr Pacey described the findings as an 'exciting step forward' but highlighted the drug has not been tested in a real-world setting to find whether it actually leads to fewer babies.
He added: 'It takes three months to produce sperm from start to finish and so if you were to start taking any pill, not just this one, you would need to have the sperm that are currently on the production line to be moved from the system. So, there will be a lag between starting to take the pill and it having its full contraceptive effects.'
However, he explained that one of the biggest challenges will be the cost of bringing the new pill to market.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medical News Today
an hour ago
- Medical News Today
Muscle loss from GLP-1 drugs like Ozempic may not be as high as thought
While past studies show that adults taking a GLP-1 medication can lose between 5-15% of their starting body weight, other research reports that a good portion of that weight loss comes from muscle loss. A new study says, via a mouse model, that muscle loss from GLP-1 medications like Ozempic may not be as high as recently thought. Researchers also found that the decrease in lean muscle mass was not all from skeletal muscles, but from other body tissues, including the polls estimate that one in every eight adults in the U.S. have taken a glucagon-like peptide-1 receptor agonist (GLP-1) — a class of prescription drugs originally used to treat type 2 diabetes that has gained popularity as a method of weight of GLP-1 medications include semaglutide, sold under the brand names Ozempic and Wegovy, and tirzepatide, sold under the brand names Zepbound and Mounjaro. Past studies show that adults taking a GLP-1 medication can lose between 5-15% of their starting body weight within one year. However, other research reports that about 25-39% of that weight loss is from muscle loss. Now, a new study recently published in the journal Cell Metabolism says, via a mouse model, that muscle loss from GLP-1 medications like Ozempic may not be as high as recently thought. Researchers also found that the decrease in lean muscle mass was not all from skeletal muscles, but from other body tissues, including the liver. Lean muscle mass loss not just from skeletal musclesFor this study, researchers used a mouse model to determine how GLP-1 medications like Ozempic affected lean muscle mass. Upon analysis, researchers found that Ozempic-related weight loss in mice resulted in a lean muscle mass decrease of about 10%, which is less than some previous studies report that as the mice lost weight, some skeletal muscles did decrease, while other muscles stayed the same. Researchers state that the muscle mass decrease is a return to baseline, as gaining fat is usually accompanied by a gain in skeletal muscle. Researchers found some mice experienced a decrease in strength in skeletal muscles that stayed almost the same researchers found that a good portion of the decrease in lean muscle mass did not come from skeletal muscles, but rather other tissues in the body, such as the liver, which they report reduced in size by almost half. It is not uncommon for the liver to decrease in size during weight loss, which can help reduce a person's risk for fatty liver disease.'If we want to really help the individuals who may be losing muscle mass, then we need to know that they're actually losing muscle mass,' Katsu Funai, PhD, associate professor of nutrition and integrative physiology in the University of Utah College of Health and the senior author on the study says in a press release. 'We have data in mice that suggest that things are not as straightforward as they might seem.'Working with a dietitian while taking GLP-1sMedical News Today spoke with Seth Kipnis, MD, FACS, FASMBS, director of bariatric and robotic surgery at Hackensack Meridian Jersey Shore University Medical Center in New Jersey, about this study, who commented that a drop in lean muscle mass is expected. Some muscle loss is inevitable'Any patient with a restricted diet and poor nutrition/protein will have a drop in muscle mass. The key of any weight loss program, surgical, medical or GLP-1 is adequate nutrition. Working with a registered dietitian is key to long-term success and avoiding complications of malnutrition.' — Seth Kipnis, MD, FACS, FASMBS'More and more people are taking these medications on a regular basis,' he continued. 'They are working well to control weight. We should know the side effects that can be caused in the long term so that patients can be counseled on how to avoid long-term issues.' Kipnis said he would like to see better long-term data as the next steps in this research. 'And are different outcomes found depending on the prescriber and the type of follow-up,' he added. 'It is our assumption that specialists in weight management and nutrition will have better outcomes than a primary care doctor that treats every disease. Obesity is a unique disease that requires specialists to manage.'Human trials needed to further analyze GLP-1s and muscle lossMNT also talked to Kais Rona, MD, a bariatric surgeon of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA.'As a physician who has treated and continues to treat many patients with GLP-1 medications such as Ozempic, I found this study quite interesting,' Rona said. 'Although the data in this study cannot be extrapolated directly to humans, it does shed some light on potentially important physiologic effects of the medication.' 'The decrease in lean mass with GLP-1 use was associated with a lesser decrease in skeletal muscle mass and a greater decrease in the size of metabolically active organs such as the liver. This can have important physiologic effects on metabolism and overall health. We also see a decrease in liver mass in patients undergoing weight loss surgery, which often leads to beneficial health effects. Importantly, this study also highlights the importance of determining the functional impact of muscle loss and whether that is reflected in a loss of strength as well.'— Kais Rona, MD'It's extremely important to continue to study the potential side effects, including the loss of lean muscle mass, associated with GLP-1 medications as it can have major effects on our healthcare system as a whole,' Rona added. 'Furthermore, we need to continue to broaden our understanding of the physiologic effects of these medications to optimize patient safety and overall outcomes.' Rona said the next best research step would be to perform randomized-controlled trials in humans to further analyze the effects of GLP-1 medications on lean mass as well as skeletal muscle mass. 'It would be important to evaluate its effects on muscle strength as well as function,' he added. 'Also to determine whether certain areas of the body are more susceptible to muscle loss as well as identifying preventive strategies to combat muscle loss.'
Reuters
an hour ago
- Reuters
US FDA approves Jazz Pharma's drug for rare brain tumor
Aug 6 (Reuters) - The U.S. Food and Drug Administration said on Wednesday that it has approved Jazz Pharmaceuticals' (JAZZ.O), opens new tab drug to treat diffuse midline glioma, a rare and aggressive tumor, in adults and children aged one year and older. This marks the first FDA approval of a systemic therapy for diffuse midline glioma with a specific mutation that has progressed after previous treatments, the agency said. Diffuse midline glioma (DMG) is a rare and aggressive brain tumor that primarily affects children and young adults. It develops in the brain's and spinal cord's midline structures, such as the brainstem, thalamus, and spinal cord. Jazz Pharmaceuticals acquired the drug in March through its $935 million purchase of Chimerix.
The Guardian
an hour ago
- The Guardian
Depression, suicides, overdoses: broad impacts of US wildfires revealed in study
New research looking at the aftermath of some of the deadliest wildfires to have struck the US in recent years has shed light on the devastating effects the disasters have on human health, with impacts that extend far beyond the official death toll and injury counts. Three studies published this week examine the long-term fallout from the Maui and Los Angeles wildfires, including depression, suicide and overdose deaths, lung damage, and deaths caused by healthcare disruptions. The August 2023 Hawaii blazes killed more than 100 people, in what was the deadliest US wildfire in more than a century, and destroyed the town of Lahaina. The fires that tore through the LA communities of Altadena and the Pacific Palisades earlier this year killed 31 people and destroyed more than 18,000 structures. Some of the new research found that the Maui fire left one in five people with lung damage, and as many as half with symptoms of depression. That study, co-led by Ruben Juarez of the University of Hawaii, looked at more than 1,100 adults six to 14 months after the Maui fire. It found lower lung function in people in areas close to the fire compared with those in lower-exposure areas, with about 22% experiencing below-normal lung function. Additionally, about 40% of people reported their health had declined since the fires, according to the study, and close to half mentioned increased fatigue and weakness, eye irritation and lung-related symptoms. 'It's a stark reminder that wildfires can leave an invisible but lasting scar on respiratory health, long after the flames are gone,' Juarez told the Associated Press in an email. During the month of the fire, 13 suicides were reported in the area, nearly double the normal suicide and overdose death rates, another study found. The study of the Los Angeles fires, led by researchers in Finland, concluded that in addition to at least 30 deaths attributed to the fire, more than 400 deaths between January and February could be blamed on the event because of interruptions in healthcare and other factors. Dr Jonathan Patz, a University of Wisconsin environmental public health researcher who was not involved with the research, said the studies add 'a really important piece to the understanding of the true health risks from these extreme climatic events'. As the climate crisis fuels worsening disasters across the US, from flooding to deadly wildfires, scientists are trying to gain a better understanding of the impacts of extreme weather events. Research into the effects of wildfire smoke has surged in recent years as massive blazes have caused orange skies and unhealthy air for millions of people from the west coast to New York. A 2021 study found that breathing wildfire smoke during pregnancy raises the risk of premature birth. Research published earlier this year found the climate crisis contributed to about 15,000 deaths from exposure to small particulate matter from wildfires and cost about $160bn between 2006 and 2020. Another study, published in 2024, determined that wildfire smoke prematurely killed more than 50,000 people in California over a decade. Kristie Ebi of the University of Washington noted that there is a growing understanding that wildfire smoke can be more toxic than standard air pollution. 'It's not just leaves and branches and trees' that are burned, she said. 'It's buildings. It's gasoline stations. It's old houses that have asbestos in them. It's automobiles. There are lots of components of wildfire smoke.' She said the study of the Maui fire suggests 'this toxicity is affecting people's long-term lung function', but noted more research is needed to look at cause and effect. Meanwhile, the research calculating rates of suicide and overdose deaths in Maui and Hawaii's four other counties found a 97% increase in both on Maui during the month of the wildfires. The total number of suicide and overdose deaths was 13 that month, most of them suicides. That's a significant increase, Ebi said. They also found a 46% increase in such deaths in all five counties, which may have been influenced by displaced Maui residents migrating to other islands, the authors said. But rates fell in the following months. In addition to the studies published this week, a new report from the University of Hawaiʻi Economic Research Organization (UHERO), which is based on nearly a year of data from surveys of 950 people, documented the challenges that persist for those affected by the Maui fire. Two years later, some have found permanent housing and greater economic stability, but many people are still displaced and have faced long-term income loss and high rent burdens. While permanent housing is increasing, poverty rates in the region have almost doubled as full-time employment has not yet fully returned to pre-fire levels and nearly 60% of households report lower income. 'Our findings show two realities unfolding side by side,' said Daniela Bond-Smith, a UHERO research economist. 'Some households are finding new footing – moving into stable housing, returning to work and regaining stability. But others are still living with deep uncertainty, especially those with limited support and population groups who had already been marginalized prior to the fires.'
